— We have everything you need: full data on over 700 000 bonds, stocks & ETFs; powerful bond screener; over 350 pricing sources among stock exchanges & OTC market; ratings & financial reports; ...

Goldman Sachs lowered the firm’s price target on Phathom Pharmaceuticals (PHAT) to $12 from $18 and keeps a Neutral rating on the shares after its FY24 results. The company’s product revenue ...

Originally available to stream on a dedicated app, “The Chosen” chose to premiere its third and fourth seasons in theaters via Fathom Entertainment — an unprecedented move for an entire ...

Craig-Hallum analyst Chase Knickerbocker lowered the firm’s price target on Phathom Pharmaceuticals (PHAT) to $19 from $27 and keeps a Buy rating on the shares. The firm notes Phathom’s Q4 ...

Revenue: US$55.3m (up by US$54.6m from FY 2023). Net loss: US$334.3m (loss widened by 66% from FY 2023). US$5.29 loss per share (further deteriorated from US$3.93 loss in FY 2023). Revenue ...

Phathom Pharmaceuticals Inc (NASDAQ:PHAT) secured FDA approval for non-erosive GERD, enhancing their product portfolio. The company reported strong commercial coverage, with over 120 million lives ...

Phathom Pharmaceuticals Inc (PHAT) reported a significant increase in revenue for Q4 2024, with net revenues reaching $29.7 million, marking an 81% sequential increase. Despite the positive revenue ...

Hello, and welcome to the Phathom Pharmaceuticals Fourth Quarter and Full Year 2024 Earnings Results Call. At this time, all participants are in a listen-only mode. After the presentation ...

Recent Business Updates and Fourth Quarter & Full Year 2024 Results: VOQUEZNA Launch Progress: Phathom achieved significant commercial progress in 2024, firmly establishing VOQUEZNA as the first ...

Phathom Pharmaceuticals, Inc. (PHAT) came out with a quarterly loss of $0.79 per share versus the Zacks Consensus Estimate of a loss of $0.98. This compares to loss of $0.80 per share a year ago.